[Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
Anti-TNF drugs are used increasingly in several diseases with immune-mediated inflammation, not only in rheumatological conditions, but also in inflammatory bowel disease and psoriasis. Different side effects have been described over the last few years, including the development of psoriasis or psoriasiform exanthemas. These drugs began to be used in paediatrics during the 90's, therefore paediatricians need to be aware of the adverse effects that may occur. We describe here a flexural psoriasis induced by both infliximab and adalimumab in a paediatric patient with Crohn's Disease. To the best of our knowledge, this is the first reported paediatric case of psoriasis triggered by an anti-TNF drug, as well as the first case of psoriasis induced by adalimumab in patients with inflammatory bowel disease.
Avila Alvarez
A
A
Servicio de Pediatría, Unidad de Gastroenterología Pediátrica, Complejo Hospitalario Universitario de A Coruña, A Coruña, España. alexavila81@hotmail.com
García-Alonso
L
L
Solar Boga
A
A
García-Silva
J
J
D000068879:Adalimumab; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab